English

• Kancera reports positive outcome of pre-IND meeting with FDA

  5 June 2025

• Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

  23 May 2025

• Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program

  20 May 2025

• Kancera reports Last Patient Last Visit in the KANDOVA study

  8 April 2025

• Kancera changes Certified Adviser to Redeye AB

  14 March 2025

• Kancera announces intention to change company name to Novakand Pharma

  7 March 2025

• Kancera signs letter of intent agreement with Recardio for licensing of KAND567 and KAND145

  7 March 2025

• Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

  21 February 2025

• Interim Report Third Quarter 2024, July 1 – September 30 Kancera AB (publ.), org.no. 556806-8851

  15 November 2024

• Kancera focuses on cardiovascular diseases

  12 November 2024